These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

68 related items for PubMed ID: 19921275

  • 1. Identification of cultivation condition to produce correctly folded form of a malaria vaccine based on Plasmodium falciparum merozoite surface protein-1 in Escherichia coli.
    Mazumdar S, Sachdeva S, Chauhan VS, Yazdani SS.
    Bioprocess Biosyst Eng; 2010 Aug; 33(6):719-30. PubMed ID: 19921275
    [Abstract] [Full Text] [Related]

  • 2. High-level production and purification of P30P2MSP1(19), an important vaccine antigen for malaria, expressed in the methylotropic yeast Pichia pastoris.
    Brady CP, Shimp RL, Miles AP, Whitmore M, Stowers AW.
    Protein Expr Purif; 2001 Dec; 23(3):468-75. PubMed ID: 11722185
    [Abstract] [Full Text] [Related]

  • 3. IgG subclass antibodies to three variants of Plasmodium falciparum merozoite surface protein-1 (PfMSP-1(19)) in an area with unstable malaria transmission in Iran.
    Mehrizi AA, Asgharpour S, Salmanian AH, Djadid ND, Zakeri S.
    Acta Trop; 2011 Aug; 119(2-3):84-90. PubMed ID: 21609709
    [Abstract] [Full Text] [Related]

  • 4. Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village.
    Perraut R, Marrama L, Diouf B, Sokhna C, Tall A, Nabeth P, Trape JF, Longacre S, Mercereau-Puijalon O.
    J Infect Dis; 2005 Jan 15; 191(2):264-71. PubMed ID: 15609237
    [Abstract] [Full Text] [Related]

  • 5. Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24.
    Gupta PK, Mukherjee P, Dhawan S, Pandey AK, Mazumdar S, Gaur D, Jain SK, Chauhan VS.
    Clin Vaccine Immunol; 2014 Jun 15; 21(6):886-97. PubMed ID: 24789797
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants.
    Sachdeva S, Mohmmed A, Dasaradhi PV, Crabb BS, Katyal A, Malhotra P, Chauhan VS.
    Vaccine; 2006 Mar 15; 24(12):2007-16. PubMed ID: 16377036
    [Abstract] [Full Text] [Related]

  • 7. Proteome analysis reveals a large merozoite surface protein-1 associated complex on the Plasmodium falciparum merozoite surface.
    Ranjan R, Chugh M, Kumar S, Singh S, Kanodia S, Hossain MJ, Korde R, Grover A, Dhawan S, Chauhan VS, Reddy VS, Mohmmed A, Malhotra P.
    J Proteome Res; 2011 Feb 04; 10(2):680-91. PubMed ID: 21175202
    [Abstract] [Full Text] [Related]

  • 8. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
    Bargieri DY, Leite JA, Lopes SC, Sbrogio-Almeida ME, Braga CJ, Ferreira LC, Soares IS, Costa FT, Rodrigues MM.
    Vaccine; 2010 Apr 01; 28(16):2818-26. PubMed ID: 20170765
    [Abstract] [Full Text] [Related]

  • 9. Plasmodium falciparum: sequence analysis of the gene encoding the C-terminus region of the merozoite surface protein-1, a potential malaria vaccine antigen, in Iranian clinical isolates.
    Mehrizi AA, Zakeri S, Salmanian AH, Sanati MH, Djadid ND.
    Exp Parasitol; 2008 Mar 01; 118(3):378-85. PubMed ID: 18053992
    [Abstract] [Full Text] [Related]

  • 10. Assistance of maltose binding protein to the in vivo folding of the disulfide-rich C-terminal fragment from Plasmodium falciparum merozoite surface protein 1 expressed in Escherichia coli.
    Planson AG, Guijarro JI, Goldberg ME, Chaffotte AF.
    Biochemistry; 2003 Nov 18; 42(45):13202-11. PubMed ID: 14609331
    [Abstract] [Full Text] [Related]

  • 11. Soluble and glyco-lipid modified baculovirus Plasmodium falciparum C-terminal merozoite surface protein 1, two forms of a leading malaria vaccine candidate.
    Bonnet S, Pêtres S, Holm I, Fontaine T, Rosario S, Roth C, Longacre S.
    Vaccine; 2006 Aug 14; 24(33-34):5997-6008. PubMed ID: 16814434
    [Abstract] [Full Text] [Related]

  • 12. Amino acid dimorphism and parasite immune evasion: cellular immune responses to a promiscuous epitope of Plasmodium falciparum merozoite surface protein 1 displaying dimorphic amino acid polymorphism are highly constrained.
    Daubenberger CA, Nickel B, Ciatto C, Grütter MG, Pöltl-Frank F, Rossi L, Siegler U, Robinson J, Kashala O, Patarroyo ME, Pluschke G.
    Eur J Immunol; 2002 Dec 14; 32(12):3667-77. PubMed ID: 12516559
    [Abstract] [Full Text] [Related]

  • 13. Production and characterization of clinical grade Escherichia coli derived Plasmodium falciparum 42 kDa merozoite surface protein 1 (MSP1(42)) in the absence of an affinity tag.
    Shimp RL, Martin LB, Zhang Y, Henderson BS, Duggan P, MacDonald NJ, Lebowitz J, Saul A, Narum DL.
    Protein Expr Purif; 2006 Nov 14; 50(1):58-67. PubMed ID: 16884920
    [Abstract] [Full Text] [Related]

  • 14. Vaccine candidate MSP-1 from Plasmodium falciparum: a redesigned 4917 bp polynucleotide enables synthesis and isolation of full-length protein from Escherichia coli and mammalian cells.
    Pan W, Ravot E, Tolle R, Frank R, Mosbach R, Türbachova I, Bujard H.
    Nucleic Acids Res; 1999 Feb 15; 27(4):1094-103. PubMed ID: 9927744
    [Abstract] [Full Text] [Related]

  • 15. Functional conservation of the malaria vaccine antigen MSP-119across distantly related Plasmodium species.
    O'Donnell RA, Saul A, Cowman AF, Crabb BS.
    Nat Med; 2000 Jan 15; 6(1):91-5. PubMed ID: 10613831
    [Abstract] [Full Text] [Related]

  • 16. Biochemical and immunological characterization of E. coli expressed 42 kDa fragment of Plasmodium vivax and P. cynomolgi bastianelli merozoite surface protein-1.
    Kaushal DC, Kaushal NA, Narula A, Kumar N, Puri SK, Dutta S, Lanar DE.
    Indian J Biochem Biophys; 2007 Dec 15; 44(6):429-36. PubMed ID: 18320841
    [Abstract] [Full Text] [Related]

  • 17. Enhanced expression of a recombinant malaria candidate vaccine in Escherichia coli by codon optimization.
    Zhou Z, Schnake P, Xiao L, Lal AA.
    Protein Expr Purif; 2004 Mar 15; 34(1):87-94. PubMed ID: 14766303
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial.
    Stowers AW, Cioce V, Shimp RL, Lawson M, Hui G, Muratova O, Kaslow DC, Robinson R, Long CA, Miller LH.
    Infect Immun; 2001 Mar 15; 69(3):1536-46. PubMed ID: 11179324
    [Abstract] [Full Text] [Related]

  • 19. Protein-protein interaction studies reveal the Plasmodium falciparum merozoite surface protein-1 region involved in a complex formation that binds to human erythrocytes.
    Paul G, Deshmukh A, Kumar Chourasia B, Kalamuddin M, Panda A, Kumar Singh S, Gupta PK, Mohmmed A, Chauhan VS, Theisen M, Malhotra P.
    Biochem J; 2018 Mar 29; 475(6):1197-1209. PubMed ID: 29511044
    [Abstract] [Full Text] [Related]

  • 20. Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development.
    Yuen D, Leung WH, Cheung R, Hashimoto C, Ng SF, Ho W, Hui G.
    Vaccine; 2007 Jan 05; 25(3):490-9. PubMed ID: 16949181
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.